FDA Approves Tregzi, First Regulatory T-Cell (Treg) Immunotherapy for Chronic GVHD Prevention, Expands Casgevy Indication to Pediatric Patients

August 9, 2026

Cell and Gene Therapy Catapult USA

Overview

On June 30, 2026, the U.S. FDA approved Tregzi, the first regulatory T-cell (Treg)-based immunotherapy designed to prevent chronic graft-versus-host disease (GVHD) and improve survival. Tregzi is a donor-derived cellular therapy comprising hematopoietic stem and progenitor cells, regulatory T cells, and conventional T cells from an HLA-matched donor. Additionally, the indication for Casgevy, a treatment for sickle cell disease or transfusion-dependent beta-thalassemia, has been expanded to include pediatric patients aged 2 years and older. These approvals mark significant advancements and broader patient access in the cell and gene therapy landscape.

In Depth

Key Findings

On June 30, 2026, the U.S. Food and Drug Administration (FDA) granted approval to Tregzi, marking it as the first regulatory T-cell (Treg)-based immunotherapy aimed at preventing chronic graft-versus-host disease (GVHD) and enhancing survival outcomes. Concurrently, the FDA announced an expanded indication for Casgevy, a gene-editing therapy for sickle cell disease or transfusion-dependent beta-thalassemia, to include pediatric patients aged 2 years and older.

Technical / Clinical Details

Tregzi is a unique donor-derived cellular therapy composed of hematopoietic stem and progenitor cells (HSPC), regulatory T cells (Tregs), and conventional T cells sourced from an HLA-matched donor. Tregs are known for their crucial role in suppressing immune responses and preventing autoimmune reactions, such as GVHD. This therapy offers a groundbreaking prophylactic strategy against chronic GVHD, a frequently severe complication following allogeneic hematopoietic stem cell transplantation (HSCT). GVHD occurs when transplanted donor immune cells attack the patient’s tissues, posing a life-threatening risk. Tregzi’s approval establishes a new paradigm in GVHD management.

Meanwhile, Casgevy is an innovative gene-editing therapy that utilizes CRISPR/Cas9 technology to modify a patient’s own hematopoietic stem cells for the treatment of sickle cell disease and transfusion-dependent beta-thalassemia. The expanded indication now includes pediatric patients aged 2 years and older. This has the potential to provide lifelong therapeutic benefits, especially for children suffering from these severe blood disorders from an early age. Casgevy aims to reactivate fetal hemoglobin production, thereby mitigating or resolving disease symptoms.

Background & Context

Chronic GVHD is a major complication after allogeneic HSCT, significantly impacting patients’ quality of life and long-term survival, with conventional preventive and treatment strategies having limitations. The approval of a Treg-based immunotherapy signifies a major advancement in transplant medicine. Furthermore, sickle cell disease and beta-thalassemia are inherited blood disorders that have historically had limited curative treatment options. The advent of gene-editing therapies like Casgevy opens up the possibility of a definitive cure for these diseases, and the expanded indication for pediatric patients raises hopes for better long-term outcomes through earlier intervention. These approvals demonstrate that the cell and gene therapy sector is rapidly maturing and delivering innovative solutions across diverse disease areas.

Strategic Significance & Outlook

The approval of Tregzi is poised to revolutionize the prevention and management of chronic GVHD, potentially dramatically improving the prognosis for patients undergoing allogeneic HSCT, enabling safer and more effective transplant procedures. The expanded indication for Casgevy in pediatric patients further extends the potential impact of gene-editing therapies in inherited blood disorders. As these therapies become more widely available, many patients are expected to find relief from the debilitating effects of these diseases and lead healthier lives. These regulatory approvals send a clear signal that cell and gene therapies are establishing new standards of care for intractable diseases.

Source: https://ct.catapult.org.uk/news/regulatory-round-up-july-2026

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.